



## Targeting Wnt Signaling in Cancer

Guest Editor:

**Dr. Robert M. Kypta**

Department of Surgery and  
Cancer, Imperial College London,  
London W12 0NN, UK; Centre for  
Cooperative Research in  
Biosciences, CIC bioGUNE, 48160  
Derio, Spain

Deadline for manuscript  
submissions:  
**closed (31 May 2019)**

### Message from the Guest Editor

Dear Colleagues,

A wide variety of approaches have been used to control Wnt signaling, not only in cancer but also in other diseases where Wnt signaling has gone awry. These approaches include prevention of ligand secretion, inhibition of receptor function, modulation of effector protein stability, and disruption of transcription factor complexes. This Special Issue seeks to highlight some of the achievements that have been made in identifying drugs that target Wnt signaling, in clinical trials involving Wnt inhibitors, and in determining potential new targets and tools that might be used to impact Wnt signaling in cancer in the future.

Dr. Robert M. Kypta  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)